Providing Today's Patients with Medicines of the Future.
Staff
2017-2019 Net Profit CAGR
Current Brands of Products
Innovative Product Candidates
Covering Class III Hospitals
Covering Other Hospitals & Medical Institutions
- Simcere to lead clinical development, regulatory submissions and commercialization of trilaciclib across all indications in Greater China - G1 to re...
On May 18, 2020, Simcere announced the collaboration with Primary Peptides, a privately held biotech company in Canada, on exclusive license to develo...
On May 15, 2020, Simcere announced that key clinical data from a strategic cooperation on KN035, also known as Envafolimab, will be released at the up...
As the ongoing Covid-19 outbreak escalates around the world, Simcere is strengthening its efforts working with overseas partners in the fight against ...